1-[4-[(4-Phenylphenyl)methoxy]phenyl]ethanone | 911412-26-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[4-[(4-Phenylphenyl)methoxy]phenyl]ethanone
• CAS: 911412-26-5
• 化学式: C₂₁H₁₈O₂
• 分子量: 302.373
• InChiKey: ICUWUYSQILPZFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-[4-[(4-Phenylphenyl)methoxy]phenyl]ethanone 在 copper(ll) bromide 作用下， 以 氯仿 、 乙酸乙酯 为溶剂， 生成 1-(4-([1,1'-biphenyl]-4-ylmethoxy)phenyl)-2-bromoethan-1-one
  参考文献：
  名称：

  Synthesis and evaluation of arylalkoxy- and biarylalkoxy-phenylamide and phenylimidazoles as potent and selective sphingosine-1-phosphate receptor subtype-1 agonists

  摘要：

  In pursuit of potent and selective sphingosine-1-phosphate receptor agonists, we have utilized previously reported phenylamide and phenylimidazole scaffolds to explore extensive side-chain modi. cations to generate new molecular entities. A number of designed molecules demonstrate good selectivity and excellent in vitro and in vivo potency in both mouse and rat models. Oral administration of the lead molecule 11c (PPI-4667) demonstrated potent and dose-responsive lymphopenia. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.073
• 作为产物：
  描述：

  联苯-4-甲醇 、 4-氟苯乙酮 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 生成 1-[4-[(4-Phenylphenyl)methoxy]phenyl]ethanone
  参考文献：
  名称：

  Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists

  摘要：

  In pursuit of a potent and highly selective sphingosine-1-phosphate receptor agonists with an improved in vivo conversion of the precursor to the active phospho-drug, we have utilized previously reported phenylamide and phenylimidazole scaffolds to identify a selectivity enhancing moiety (SEM) and selectivity enhancing orientation (SEO) within both pharmacophores. SEM and SEO have allowed for over 100 to 500-fold improvement in selectivity for S1P receptor subtype 1 over subtype 3. Utility of SEM and SEO and further SAR study allowed for discovery of a potent and selective preclinical candidate PPI-4955 (21b) with an excellent in vivo potency and dose responsiveness and markedly improved overall in vivo pharmacodynamic properties upon oral administration. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.02.098

文献信息

• Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
  申请人：Evindar Ghotas

  公开号：US20060223866A1

  公开（公告）日：2006-10-05

  The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprising these compounds.

  本发明涉及调节S1P1受体活性的化合物，使用这些化合物治疗与S1P1受体信号传导相关的疾病，并包括这些化合物的制药组合物。
• Synthesis and evaluation of arylalkoxy- and biarylalkoxy-phenylamide and phenylimidazoles as potent and selective sphingosine-1-phosphate receptor subtype-1 agonists
  作者：Ghotas Evindar、Alexander L. Satz、Sylvie G. Bernier、Malcolm J. Kavarana、Elisabeth Doyle、Jeanine Lorusso、Nazbeh Taghizadeh、Keith Halley、Amy Hutchings、Michael S. Kelley、Albion D. Wright、Ashis K. Saha、Gerhard Hannig、Barry A. Morgan、William F. Westlin

  DOI：10.1016/j.bmcl.2009.02.073

  日期：2009.4

  In pursuit of potent and selective sphingosine-1-phosphate receptor agonists, we have utilized previously reported phenylamide and phenylimidazole scaffolds to explore extensive side-chain modi. cations to generate new molecular entities. A number of designed molecules demonstrate good selectivity and excellent in vitro and in vivo potency in both mouse and rat models. Oral administration of the lead molecule 11c (PPI-4667) demonstrated potent and dose-responsive lymphopenia. (c) 2009 Elsevier Ltd. All rights reserved.
• [EN] METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY<br/>[FR] PROCEDES ET COMPOSITIONS PERMETTANT DE MODULER L'ACTIVITE DU RECEPTEUR DU SPHINGOSINE-1-PHOSPHATE (S1P)
  申请人：PRAECIS PHARM INC

  公开号：WO2007092190A2

  公开（公告）日：2007-08-16

  [EN] The present invention relates to compounds which modulate the activity of the SlPl receptor, the use of these compounds for treating conditions associated with signaling through the SlPl receptor, and pharmaceutical compositions comprising these compounds.
  [FR] La présente invention concerne des composés qui modulent l'activité du récepteur du récepteur du SIPI, l'utilisation de ces composés pour traiter des états associés à la signalisation par le récepteur du SIPI et des compositions pharmaceutiques comprenant ces composés.
• Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists
  作者：Ghotas Evindar、Sylvie G. Bernier、Elisabeth Doyle、Malcolm J. Kavarana、Alexander L. Satz、Jeanine Lorusso、Heather S. Blanchette、Ashis K. Saha、Gerhard Hannig、Barry A. Morgan、William F. Westlin

  DOI：10.1016/j.bmcl.2010.02.098

  日期：2010.4

  In pursuit of a potent and highly selective sphingosine-1-phosphate receptor agonists with an improved in vivo conversion of the precursor to the active phospho-drug, we have utilized previously reported phenylamide and phenylimidazole scaffolds to identify a selectivity enhancing moiety (SEM) and selectivity enhancing orientation (SEO) within both pharmacophores. SEM and SEO have allowed for over 100 to 500-fold improvement in selectivity for S1P receptor subtype 1 over subtype 3. Utility of SEM and SEO and further SAR study allowed for discovery of a potent and selective preclinical candidate PPI-4955 (21b) with an excellent in vivo potency and dose responsiveness and markedly improved overall in vivo pharmacodynamic properties upon oral administration. (C) 2010 Elsevier Ltd. All rights reserved.